Predicting disease progression after nephrectomy for localized renal cell carcinoma

The utility of prognostic models and molecular biomarkers

Paul L. Crispen, Stephen A. Boorjian, Christine M. Lohse, Bradley C. Leibovich, Eugene D Kwon

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Disease progression after nephrectomy for pathologically localized renal cell carcinoma (RCC) is associated with a significant mortality rate, given the limited efficacy of available treatment regimens for metastatic disease. As such, several adjuvant trials have been designed to treat patients at particularly high risk for postsurgical RCC progression. Several different prognostic models designed to identify patients at high risk of disease progression are available. Although these available predictive models provide a reasonable assessment of patients' risks of disease progression, the accuracy of these models may further be improved via the incorporation of molecular prognostic biomarkers. Although numerous candidate molecules have been described, few have been specifically assessed for the association with disease progression after nephrectomy. IMP-3, CXCR3, p53, Survivin, cIAP1, B7-H1, and B7-H4 have all been associated with disease progression after nephrectomy. The incorporation of 1 or several of these biomarkers may increase the accuracy of currently available prognostic models and thereby facilitate the appropriate use of adjuvant therapies aimed at preventing future disease progression. As such, the authors review the current prognostic tools for predicting disease progression for localized RCC, and detail studies to date that have evaluated various biomarkers in this setting.

Original languageEnglish (US)
Pages (from-to)450-460
Number of pages11
JournalCancer
Volume113
Issue number3
DOIs
StatePublished - Aug 1 2008

Fingerprint

Molecular Models
Nephrectomy
Renal Cell Carcinoma
Disease Progression
Biomarkers
Inosine Monophosphate
Mortality

Keywords

  • Adjuvant trials
  • Disease progression
  • Molecular biomarkers
  • Prognosis
  • Renal cell carcinoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Predicting disease progression after nephrectomy for localized renal cell carcinoma : The utility of prognostic models and molecular biomarkers. / Crispen, Paul L.; Boorjian, Stephen A.; Lohse, Christine M.; Leibovich, Bradley C.; Kwon, Eugene D.

In: Cancer, Vol. 113, No. 3, 01.08.2008, p. 450-460.

Research output: Contribution to journalArticle

Crispen, Paul L. ; Boorjian, Stephen A. ; Lohse, Christine M. ; Leibovich, Bradley C. ; Kwon, Eugene D. / Predicting disease progression after nephrectomy for localized renal cell carcinoma : The utility of prognostic models and molecular biomarkers. In: Cancer. 2008 ; Vol. 113, No. 3. pp. 450-460.
@article{b06a68cde59047369b0fe8560e2a5bc5,
title = "Predicting disease progression after nephrectomy for localized renal cell carcinoma: The utility of prognostic models and molecular biomarkers",
abstract = "Disease progression after nephrectomy for pathologically localized renal cell carcinoma (RCC) is associated with a significant mortality rate, given the limited efficacy of available treatment regimens for metastatic disease. As such, several adjuvant trials have been designed to treat patients at particularly high risk for postsurgical RCC progression. Several different prognostic models designed to identify patients at high risk of disease progression are available. Although these available predictive models provide a reasonable assessment of patients' risks of disease progression, the accuracy of these models may further be improved via the incorporation of molecular prognostic biomarkers. Although numerous candidate molecules have been described, few have been specifically assessed for the association with disease progression after nephrectomy. IMP-3, CXCR3, p53, Survivin, cIAP1, B7-H1, and B7-H4 have all been associated with disease progression after nephrectomy. The incorporation of 1 or several of these biomarkers may increase the accuracy of currently available prognostic models and thereby facilitate the appropriate use of adjuvant therapies aimed at preventing future disease progression. As such, the authors review the current prognostic tools for predicting disease progression for localized RCC, and detail studies to date that have evaluated various biomarkers in this setting.",
keywords = "Adjuvant trials, Disease progression, Molecular biomarkers, Prognosis, Renal cell carcinoma",
author = "Crispen, {Paul L.} and Boorjian, {Stephen A.} and Lohse, {Christine M.} and Leibovich, {Bradley C.} and Kwon, {Eugene D}",
year = "2008",
month = "8",
day = "1",
doi = "10.1002/cncr.23566",
language = "English (US)",
volume = "113",
pages = "450--460",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - Predicting disease progression after nephrectomy for localized renal cell carcinoma

T2 - The utility of prognostic models and molecular biomarkers

AU - Crispen, Paul L.

AU - Boorjian, Stephen A.

AU - Lohse, Christine M.

AU - Leibovich, Bradley C.

AU - Kwon, Eugene D

PY - 2008/8/1

Y1 - 2008/8/1

N2 - Disease progression after nephrectomy for pathologically localized renal cell carcinoma (RCC) is associated with a significant mortality rate, given the limited efficacy of available treatment regimens for metastatic disease. As such, several adjuvant trials have been designed to treat patients at particularly high risk for postsurgical RCC progression. Several different prognostic models designed to identify patients at high risk of disease progression are available. Although these available predictive models provide a reasonable assessment of patients' risks of disease progression, the accuracy of these models may further be improved via the incorporation of molecular prognostic biomarkers. Although numerous candidate molecules have been described, few have been specifically assessed for the association with disease progression after nephrectomy. IMP-3, CXCR3, p53, Survivin, cIAP1, B7-H1, and B7-H4 have all been associated with disease progression after nephrectomy. The incorporation of 1 or several of these biomarkers may increase the accuracy of currently available prognostic models and thereby facilitate the appropriate use of adjuvant therapies aimed at preventing future disease progression. As such, the authors review the current prognostic tools for predicting disease progression for localized RCC, and detail studies to date that have evaluated various biomarkers in this setting.

AB - Disease progression after nephrectomy for pathologically localized renal cell carcinoma (RCC) is associated with a significant mortality rate, given the limited efficacy of available treatment regimens for metastatic disease. As such, several adjuvant trials have been designed to treat patients at particularly high risk for postsurgical RCC progression. Several different prognostic models designed to identify patients at high risk of disease progression are available. Although these available predictive models provide a reasonable assessment of patients' risks of disease progression, the accuracy of these models may further be improved via the incorporation of molecular prognostic biomarkers. Although numerous candidate molecules have been described, few have been specifically assessed for the association with disease progression after nephrectomy. IMP-3, CXCR3, p53, Survivin, cIAP1, B7-H1, and B7-H4 have all been associated with disease progression after nephrectomy. The incorporation of 1 or several of these biomarkers may increase the accuracy of currently available prognostic models and thereby facilitate the appropriate use of adjuvant therapies aimed at preventing future disease progression. As such, the authors review the current prognostic tools for predicting disease progression for localized RCC, and detail studies to date that have evaluated various biomarkers in this setting.

KW - Adjuvant trials

KW - Disease progression

KW - Molecular biomarkers

KW - Prognosis

KW - Renal cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=46449137115&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=46449137115&partnerID=8YFLogxK

U2 - 10.1002/cncr.23566

DO - 10.1002/cncr.23566

M3 - Article

VL - 113

SP - 450

EP - 460

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 3

ER -